The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

NCT07678645 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Primary Biliary Cholangitis (PBC)
Primary Sclerosing Cholangitis (PSC)
Atopic Dermatitis (AD)

Interventions

DRUG: Upadacitinib 15 MG

Sponsor

RenJi Hospital